Arcutis Initiates Phase 3 Clinical TrialOf Topical Roflumilast Cream As Potential Treatment For Atopic Dermatitis In Pediatric Patients Between The Ages Of Two AArcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical compand Five Years